Core Insights - CytoDyn Inc. is set to present clinical data at the San Antonio Breast Cancer Symposium (SABCS) demonstrating sustained remission in patients with metastatic or locally advanced triple-negative breast cancer (mTNBC) following immune checkpoint inhibitor therapy with or after leronlimab treatment [1][3] Company Overview - CytoDyn is a clinical-stage oncology company focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, with potential applications in various cancers, including mTNBC and colorectal cancer [1][6] - The company aims to improve patients' quality of life through therapeutic innovation and is committed to integrity, responsibility, and service [6] Clinical Findings - mTNBC is associated with a poor prognosis, and the efficacy of immune checkpoint inhibitors is reduced in patients with low levels of PD-L1 [2] - Previous trials suggest that leronlimab treatment may increase PD-L1 levels, potentially improving survival when combined with immune checkpoint inhibitors [2] - The CEO of CytoDyn highlighted the promise of using leronlimab in combination with immune checkpoint inhibitors, noting that some patients have shown sustained long-term remission, including three individuals with no current evidence of disease [3] Presentation Details - The poster presentation will be led by Dr. Milana V. Dolezal from Stanford University and will take place on December 12, 2025, at the SABCS [8] - A copy of the presentation will be available on CytoDyn's website after the symposium [5]

Core Insights - CytoDyn Inc. is set to present clinical data at the San Antonio Breast Cancer Symposium, showcasing sustained remission in patients with metastatic triple-negative breast cancer (mTNBC) following treatment with leronlimab and immune checkpoint inhibitors [1][3] Company Overview - CytoDyn is a clinical-stage oncology company focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, with potential applications in various cancers, including mTNBC and colorectal cancer [1][6] Clinical Data Presentation - Dr. Milana V. Dolezal from Stanford University will present a poster detailing the prolonged survival of mTNBC patients treated with leronlimab in combination with PD-L1/PD-1 immune checkpoint inhibitors, highlighting the upregulation of PD-L1 levels [2][9] - The poster presentation is scheduled for December 12, 2025, from 12:30 PM to 2:00 PM CST at the Exhibit Hall [9] Treatment Efficacy - The use of leronlimab has been associated with increased PD-L1 levels, which may enhance the efficacy of immune checkpoint inhibitors in mTNBC patients, particularly those with low PD-L1 expression [2][3]